New therapeutic approaches for Hodgkin lymphoma - European Medical Journal

New therapeutic approaches for Hodgkin lymphoma

Hematology
At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses clinical trials of new treatments for Hodgkin lymphoma (HL). Topics of interest include bendamustine-containing regimen (BeGEV) as induction chemotherapy prior to autologous stem cell transplantation for patients with relapsed or refractory HL and the phase 1 trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for elderly patients with HL.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now